臺北榮民總醫院醫學研究部

:::

首頁 > 研究單位 > 研究室 > 血管生物學暨血管醫學研究室

血管生物學暨血管醫學研究室

A- A A+

教職：
TEL: +886-2-28757434*329 E-mail: jwchen@vghtpe.gov.tw
主持人：陳肇文
現職：
	臺北榮民總醫院醫學研究部臨床研究科主任(2013~)
	臺北榮民總醫院醫學研究部精準醫學研發中心主任(2017~)
	臺北榮民總醫院內科部心臟內科兼任主治醫師(2009~)
	國立陽明大學醫學院藥理學研究所專任教授 (2007~)
	國立陽明大學急重症所(2007~)/醫學系(2013~)/臨醫所(2019~)合聘教授
	國立陽明大學心血管疾病研究中心主任(2017~)
經歷：
	臺北榮民總醫院內科部住院醫師(1986-1989)
	臺北榮民總醫院心臟內科住院總醫師(1989-1991)
	臺北榮民總醫院心臟內科臨床研究員(1991-1993)
	臺北榮民總醫院內科部心臟內科主治醫師(1993~2009)
	美國史丹佛大學醫學院心血管研究中心博士後研究員(1997-1998)
	國立陽明大學醫學院醫學系助理教授(1998-2003)
	國立陽明大學醫學院醫學系專任副教授 (2003-2006)
	國立陽明大學醫學院醫學系專任教授 (2006~2007)
	國立陽大學心血管疾病研究中心副主任(2007-2017)
	國立陽明大學研發處副研發長兼智財服務組長(2011-2015)

《Awards since 2009 》

Great Academic Achievement Award at the 50th Anniversary of Taipei Veterans General [臺北榮民總醫院五十週年院慶重大學術成就獎), Taiwan, ROC, 2009 中華民國行政院退除役官兵輔導委員會99年度優良醫師, 2010

Teacher Excellent Academic Achievement Award Program, National Yang-Ming University (國立陽明大學教師學術卓越獎勵), Taiwan, ROC, 2010-2019

Futurtech Breakthrough Award (未來科技突破獎), Ministry of Science and Technology, Executive Yuan (中華民國行政院科技部), Taiwan ROC, 2018

《Future plan》

Molecular biomarkers for diagnosis and risk stratification in cardiovascular disease (北榮內科部 &醫研部) Genetics and pharmacogenetics in clinical treatment of cardiovascular diseases (中研院生醫所 , 陽明大學藥理所)

Novel drug treatment and vascular progenitor cell therapy for in clinical atherosclerosis disease (北榮醫研部,陽明大學藥理所,陽明大學心血管疾病研究中心)

《研究興趣》

一、血管生物學
血管內皮細胞功能及細胞內信息傳導
氧化壓力(oxidative stress)與動脈硬化之發生
血管前驅細胞(vascular progenitor cell)及血管修補
組織缺血及血管新生(angiogenesis)

二、血管醫學 (Vascular medicine)
高血壓及動脈硬化疾病之遺傳(genetics)
動脈硬化疾病之生物標誌(biosignature)及臨床預後指標
高血壓及動脈硬化疾病之介入及藥物治療
心血管疾病之細胞治療(cell therapy)

《專利》

高血壓、三酸甘油脂偏高及代謝症候群之風險預測

中華民國專利證書號數：TW I357442

發明人：潘文涵 (TW) PAN, WEN HARN；周玉山 (TW) JOU, YUH SHAN；陳肇文 (TW) CHEN, JAW WEN；范盛娟 (TW) FANN, CATHY S J

專利期間: 2012,02,01 ~2025,10,25

影響血管收縮素轉化酶活性及對血管收縮素轉化酶活性抑制劑藥物反應之基因多型性及其方法

中華民國專利證書號數：TW I392741

發明人：潘文涵、鍾加明、陳肇文

專利期間: 2012,02,01 ~2025,10,25

治療高血壓的醫藥組合物及方法

中華人民共和國專利授權公開號：CN102869360 B

專利合作條約 (PCT) 編號: PCT/CN2011/073560

發明人：陈肇文, 王锡杰, 庄欣怡

發佈日期 : 2015年3月25日

治療高血壓的醫藥組合物及方法

日本特許出願的番號: 特願 2013-508361

發明人：陳肇文, 王錫傑, 莊欣怡

發佈日期 : 2015年11月5日

巨噬細胞發炎蛋白-1β(MIP-1β)抑制劑用於促進血管新生以改善組織缺血及糖尿病血管病變的用途

中華民國專利證書號數：TW I566780

發明人：陳肇文,張婷婷

專利期間: 2017/1/21 ~ 2035/10/19

巨噬細胞發炎蛋白-1β(MIP-1β)抑制劑用以保護胰臟及防止血糖升高的用途

中華民國專利證書號數：TW I576112

發明人：陳肇文,張婷婷

專利期間: 2017/1/21 ~ 2035/10/19

巨噬細胞發炎蛋白-1β(MIP-1β)抑制劑用以用於治療及控管動脈粥狀硬化之用途

中華民國專利證書號數：TW I648064

發明人：陳肇文

專利期間: 2019/1/21 ~ 2037/8/19

《近期研究著作》
Jaw-Wen Chen M.D. (陳肇文) SCI原著論文 232篇, 通訊作者 83篇,平均 Citation 12.4/篇, 平均 Impact points 4.3/篇 (~2014-12-31) Major publications since 2015 (* Corresponding author) Leu HB, Chung CM, Lin SJ, Chiang KM, Yang HC, Ho HY, Ting CT, Lin TH, Sheu SH, Tsai WC, Chen JH, Yin WH, Chiu TY, Chen CI, Fann CS, Chen YT, Pan WH, Chen JW. Association of circadian genes with diurnal blood pressure changes and non-dipper essential hypertension: a genetic association with young-onset hypertension. Hypertens Res. 2015 Feb;38(2):155-62. (SCI) Huang SS, Chan WL, Leu HB, Huang PH, Lin SJ, Chen JW. Serum bilirubin levels predict future development of metabolic syndrome in healthy middle-aged non-smoking men. Am J Med. 2015 Oct;128(10):1138.e35-41. (SCI) Wu TC, Chan JS, Lee CY, Leu HB, Huang PH, Chen JS, Chen JW. Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice. Cardiovasc Diabetol. 2015; 14(1): 81. (SCI) Huang CC, Chung, CM, Hung SI, Pan WH, Leu HB, Huang PH, Leu HB, Yang CY, Li SY, Chen YC, Wu TC, Lin SJ, Chen JW. Clinical and genetic factors associated with thiazide-induced hyponatremia. Medicine, 2015;94(34): e1422. (SCI) Chang TT, Wu TC, Huang PH, Lin CP, Chen JS, Lin LY, Lin SJ, Chen JW. Direct renin inhibition with aliskiren improves ischemia-induced neovasculogenesis in diabetic animals via the sdf-1 related mechanism. PLoS one, 2015; 10(8): e0136627. (SCI) Huang CC, Huang CC, Yang YY, Lin SJ, Chen JW. The influence of gender on the communication skills assessment of medical students. Eur J Intern Med. 2015 Nov;26(9):670-4. (SCI) Huang CC, Leu HB, Huang PH, Lin LY, Wu TC, Lin SJ, Chen JW. Hypertension subtypes modify metabolic response to thiazide diuretics. Eur J Clin Invest. 2016 Jan;46(1):80-91. (SCI) Yin WH, Chen P, Yeh HI, Wang KY, Hung YJ, Tseng WK, Wen MS, Wu TC, Wu CC, Cheng SM, Chen JW. Combination with low-dose dextromethorphan improves the effect of amlodipine monotherapy in clinical hypertension: a first-in-human, concept-proven, prospective, dose-escalation, multicenter study. Medicine (Baltimore). 2016 Mar;95(12):e3234. (SCI) Chang TT, Wu TC, Huang PH, Chen JS, Lin LY, Lin SJ, Chen JW.* Aliskiren directly improves endothelial progenitor cell function from Type II diabetic patients. Eur J Clin Invest. 2016 Jun;46(6):544-54. (SCI) Chang TT, Chen JW.Emerging role of chemokine CC motif ligand 4 related mechanisms in diabetes mellitus and cardiovascular disease: friends or foes? Cardiovasc Diabetol. 2016 Aug 24;15(1):117. (SCI) Wu TC, Lee CY, Lin SJ, Chen JW. Aliskiren Inhibits Neointimal Matrix Metalloproteinases in Experimental Atherosclerosis. Acta Cardiol Sin. 2016 Sep;32(5):586-593.(SCI) Chang CC, Hsu CY, Chang TY, Huang PH, Liu LK, Chen LK, Chen JW, Lin SJ. Association between low-grade albuminuria and frailty among community-dwelling middle-aged and older people: a cross-sectional analysis from I-Lan Longitudinal Aging Study. Sci Rep. 2016 Dec 21;6:39434. (SCI) Leu HB, Yin WH, Tseng WK, Wu YW, Lin TH, Yeh HI, Chang KC, Wang JH, Wu CC, Chen JW. Identification of new biosignatures for clinical outcomes in stable coronary artery disease - The study protocol and initial observations of a prospective follow-up study in Taiwan. BMC Cardiovasc Disord. 2017 Jan 28;17(1):42. (SCI) Huang CC, Leu HB, Yin WH, Tseng WK, Wu YW, Lin TH, Yeh HI, Chang KC, Wang JH, Wu CC, Chen JW. Optimal achieved blood pressure for patients with stable coronary artery disease. Sci Rep. 2017 Aug 31;7(1):10137. (SCI) Wu TC, Chiang CY, Chan JS, Lee CY, Leu HB, Huang PH, Chen JS, Lin SJ, Chen JW* Tocilizumab, a Humanized Monoclonal Antibody Against the Interleukin-6 Receptor, Inhibits High Glucose-Induced Vascular Smooth Muscle Cell Migration Through Mitogen-Activated Protein Kinase Signaling Pathways. J Interferon Cytokine Res. 2018 Nov;38(11):510-516. (SCI) Wu TC, Chang CC, Leu HB, Huang PH, Lin SJ, Chen JW. Phorbol ester-induced angiogenesis of endothelial progenitor cells: The role of NADPH oxidase-mediated, redox-related matrix metalloproteinase pathways. PLoS One. 2019 Jan 15;14(1):e0209426 Chang TT, Lin LY, Chen JW*. Inhibition of macrophage inflammatory protein-1β improves endothelial progenitor cell function and ischemia-induced angiogenesis in diabetes. Angiogenesis. 2019 Feb; 22(1):53-65 (SCI) Hsu CY, Tseng WK, Wu YW, Lin TH, Yeh HI, Chang KC, Wang JH, Chou RH, Huang CY, Huang PH, Leu HB, Yin WH, Wu CC, Lin SJ, Chen JW*. circulating tnfsf14 (tumor necrosis factor superfamily 14) predicts clinical outcome in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol. 2019 Jun;39(6):1240-1252. (SCI)

《近期研究著作》

Jaw-Wen Chen M.D. (陳肇文) SCI原著論文 232篇, 通訊作者 83篇,平均 Citation 12.4/篇, 平均 Impact points 4.3/篇 (~2014-12-31)

Major publications since 2015 (* Corresponding author)

Leu HB, Chung CM, Lin SJ, Chiang KM, Yang HC, Ho HY, Ting CT, Lin TH, Sheu SH, Tsai WC, Chen JH, Yin WH, Chiu TY, Chen CI, Fann CS, Chen YT, Pan WH, Chen JW*. Association of circadian genes with diurnal blood pressure changes and non-dipper essential hypertension: a genetic association with young-onset hypertension. Hypertens Res. 2015 Feb;38(2):155-62. (SCI)
Huang SS, Chan WL, Leu HB, Huang PH, Lin SJ, Chen JW*. Serum bilirubin levels predict future development of metabolic syndrome in healthy middle-aged non-smoking men. Am J Med. 2015 Oct;128(10):1138.e35-41. (SCI)
Wu TC, Chan JS, Lee CY, Leu HB, Huang PH, Chen JS, Chen JW*. Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice. Cardiovasc Diabetol. 2015; 14(1): 81. (SCI)
Huang CC, Chung, CM, Hung SI, Pan WH, Leu HB, Huang PH, Leu HB, Yang CY, Li SY, Chen YC, Wu TC, Lin SJ, Chen JW*. Clinical and genetic factors associated with thiazide-induced hyponatremia. Medicine, 2015;94(34): e1422. (SCI)
Chang TT, Wu TC, Huang PH, Lin CP, Chen JS, Lin LY, Lin SJ, Chen JW*. Direct renin inhibition with aliskiren improves ischemia-induced neovasculogenesis in diabetic animals via the sdf-1 related mechanism. PLoS one, 2015; 10(8): e0136627. (SCI)
Huang CC, Huang CC, Yang YY, Lin SJ, Chen JW*. The influence of gender on the communication skills assessment of medical students. Eur J Intern Med. 2015 Nov;26(9):670-4. (SCI)
Huang CC, Leu HB, Huang PH, Lin LY, Wu TC, Lin SJ, Chen JW*. Hypertension subtypes modify metabolic response to thiazide diuretics. Eur J Clin Invest. 2016 Jan;46(1):80-91. (SCI)
Yin WH, Chen P, Yeh HI, Wang KY, Hung YJ, Tseng WK, Wen MS, Wu TC, Wu CC, Cheng SM, Chen JW*. Combination with low-dose dextromethorphan improves the effect of amlodipine monotherapy in clinical hypertension: a first-in-human, concept-proven, prospective, dose-escalation, multicenter study. Medicine (Baltimore). 2016 Mar;95(12):e3234. (SCI)
Chang TT, Wu TC, Huang PH, Chen JS, Lin LY, Lin SJ, Chen JW*. Aliskiren directly improves endothelial progenitor cell function from Type II diabetic patients. Eur J Clin Invest. 2016 Jun;46(6):544-54. (SCI)
Chang TT, Chen JW*.Emerging role of chemokine CC motif ligand 4 related mechanisms in diabetes mellitus and cardiovascular disease: friends or foes? Cardiovasc Diabetol. 2016 Aug 24;15(1):117. (SCI)
Wu TC, Lee CY, Lin SJ, Chen JW*. Aliskiren Inhibits Neointimal Matrix Metalloproteinases in Experimental Atherosclerosis. Acta Cardiol Sin. 2016 Sep;32(5):586-593.(SCI)
Chang CC, Hsu CY, Chang TY, Huang PH, Liu LK, Chen LK, Chen JW*, Lin SJ*. Association between low-grade albuminuria and frailty among community-dwelling middle-aged and older people: a cross-sectional analysis from I-Lan Longitudinal Aging Study. Sci Rep. 2016 Dec 21;6:39434. (SCI)
Leu HB, Yin WH, Tseng WK, Wu YW, Lin TH, Yeh HI, Chang KC, Wang JH, Wu CC, Chen JW*. Identification of new biosignatures for clinical outcomes in stable coronary artery disease - The study protocol and initial observations of a prospective follow-up study in Taiwan. BMC Cardiovasc Disord. 2017 Jan 28;17(1):42. (SCI)
Huang CC, Leu HB, Yin WH, Tseng WK, Wu YW, Lin TH, Yeh HI, Chang KC, Wang JH, Wu CC, Chen JW*. Optimal achieved blood pressure for patients with stable coronary artery disease. Sci Rep. 2017 Aug 31;7(1):10137. (SCI)
Wu TC, Chiang CY, Chan JS, Lee CY, Leu HB, Huang PH, Chen JS, Lin SJ, Chen JW* Tocilizumab, a Humanized Monoclonal Antibody Against the Interleukin-6 Receptor, Inhibits High Glucose-Induced Vascular Smooth Muscle Cell Migration Through Mitogen-Activated Protein Kinase Signaling Pathways. J Interferon Cytokine Res. 2018 Nov;38(11):510-516. (SCI)
Wu TC, Chang CC, Leu HB, Huang PH, Lin SJ, Chen JW*. Phorbol ester-induced angiogenesis of endothelial progenitor cells: The role of NADPH oxidase-mediated, redox-related matrix metalloproteinase pathways. PLoS One. 2019 Jan 15;14(1):e0209426
Chang TT, Lin LY, Chen JW*. Inhibition of macrophage inflammatory protein-1β improves endothelial progenitor cell function and ischemia-induced angiogenesis in diabetes. Angiogenesis. 2019 Feb; 22(1):53-65 (SCI)
Hsu CY, Tseng WK, Wu YW, Lin TH, Yeh HI, Chang KC, Wang JH, Chou RH, Huang CY, Huang PH, Leu HB*, Yin WH, Wu CC, Lin SJ, Chen JW*. circulating tnfsf14 (tumor necrosis factor superfamily 14) predicts clinical outcome in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol. 2019 Jun;39(6):1240-1252. (SCI)

最後更新： 2019/08/08 10:22:58